Form 4: United Therapeutics EVP Exercises Share Tracking Awards Under 10b5-1 Plan
SEC Form 4 Filing
Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards for 7,700 shares under a pre-arranged 10b5-1 plan.
Summary
- Paul A. Mahon, the EVP & General Counsel of United Therapeutics Corporation, executed a transaction involving share tracking awards on February 20, 2025.
- The transaction involved the exercise of 7,700 share tracking awards at a price of $163.30.
- These awards were exercised under a pre-arranged 10b5-1 plan established on June 20, 2024.
- Following the transaction, Mahon directly owns 36,710 shares of Common Stock.
- Mahon also owns 6,550 share tracking awards.
- Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.
Sentiment
Score: 7
Explanation: The document reflects routine executive compensation activity under a pre-arranged plan, suggesting stability and adherence to regulatory guidelines. The sentiment is neutral to slightly positive.
Positives
- The transaction was executed under a pre-arranged 10b5-1 plan, indicating a planned and transparent approach to trading.
Industry Context
Executive compensation and trading activity are closely monitored in the pharmaceutical industry, especially for companies like United Therapeutics that are subject to regulatory scrutiny and have significant growth potential.
Comparison to Industry Standards
- Executive stock option and award exercises are common in publicly traded companies.
- The use of 10b5-1 plans is a standard practice to allow insiders to trade company stock without concerns about insider trading violations.
- The specific terms of share tracking awards (cash-settled, non-dilutive) are tailored to the company's compensation strategy and shareholder interests.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as share tracking awards are cash-settled and non-dilutive.
- The exercise of awards provides compensation to the executive, aligning their interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/13/2016 | Date exercisable for Share Tracking Award |
| 06/20/2024 | Date of pre-arranged 10b5-1 plan entered into by the reporting person |
| 03/13/2025 | Expiration date for Share Tracking Award |
| 02/20/2025 | Date of transaction (exercise of share tracking awards) |
| 02/21/2025 | Date of signature |
Keywords
Share Tracking Awards, United Therapeutics, Form 4, 10b5-1 Plan, Executive Compensation, UTHR, Mahon, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.